New Immune-Targeting injection tested in healthy people for first time

NCT ID NCT07058779

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests a single dose of SSS55 injection in 26 healthy adults in China. The main goal is to check if it is safe and how the body handles it. Researchers will also look at how it affects the immune system. This is a first step before testing it in people with diseases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SSS55 injection (targets complement C3b, a part of the immune system)

What this could lead to

If safe, this could pave the way for future studies of SSS55 in diseases where the immune system attacks the body, like certain autoimmune conditions.

What could go wrong

This is a very early Phase 1 trial in only 26 healthy people, so it cannot tell us if SSS55 works for any disease. Side effects are unknown and may occur.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SAFETY ISSUES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai General Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••